Anaplastic Lymphoma Kinase in Cutaneous Malignancies

• Main Authors: Severine Cao, Vinod E. Nambudiri
• Format: Article
• Language: English
• Published: MDPI AG 2017-09-01
• Series: Cancers
• Subjects: anaplastic lymphoma kinase; cutaneous malignancy; anaplastic large cell lymphoma; crizotinib
• Online Access: https://www.mdpi.com/2072-6694/9/9/123

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that has been implicated in the pathogenesis of a variety of neoplasms. As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic ALK mutations subsequently coming to attention in the development of many other hematologic and solid organ malignancies. ALK has now been shown to play a role in the pathogenesis of several cutaneous malignancies, including secondary cutaneous systemic anaplastic large-cell lymphoma (ALCL) and primary cutaneous ALCL, melanoma, spitzoid tumors, epithelioid fibrous histiocytoma, Merkel cell carcinoma, and basal cell carcinoma. The characterization of ALK-positivity in these cutaneous malignancies presents exciting opportunities for utilizing ALK-targeted inhibitors in the treatment of these diseases.